Edgewise Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

EWTX$46.53-4.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)


· · Three months ended June 30, · · Six months ended June 30,
· · 2026 · · 2025 · · 2026 · · 2025

Operating expenses · · · · · · · · · ·
Research and development	$47,548	$33,558	$90,199	$70,315
General and administrative	14,395	9,052	25,859	18,254
Total operating expenses	61,943	42,610	116,058	88,569

Loss from operations	(61,943)	(42,610)	(116,058)	(88,569)

Other income
Interest income	4,616	6,495	9,718	11,656
Total other income	4,616	6,495	9,718	11,656

Net loss	(57,327)	(36,115)	(106,340)	(76,913)

Other comprehensive income (loss):
Unrealized loss on available-for-sale securities, net	(248)	(197)	(1,177)	(216)
Total comprehensive loss	$(57,575)	$(36,312)	$(107,517)	$(77,129)

Net loss per share, basic and diluted	$(0.53)	$(0.34)	$(0.99)	$(0.77)
Weighted-average shares outstanding, basic and diluted	107,669,774	104,940,493	107,394,769	100,062,373

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.